Mavenir Launches Open RAN Intelligent Controller (O-RIC) Offering Enabling Service Differentiation and Network Resource Optimization
Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, today announced the availability of its O-RAN alliance Radio Access Network Intelligent Controller (RIC), a next-generation network intelligence offering for Open RAN. Mavenir O-RIC enables the creation of differentiated services through open APIs, which enable intelligent closed-loop end-to-end network tuning to optimize network performance, increase cost efficiency and maximize the user experience. Mavenir’s O-RIC offers Network Intelligence as a Service (NIaaS) that provides deep, fine-grained insights about the network and enables building solutions with advanced state of art intelligence. Open RAN networks can also now generate new class-of-service revenue streams by adaptively reacting in near-real time to dynamic changes in network, traffic, and load patterns. Mavenir’s O-RIC is currently in deployment with two, tier one Communications Service Providers (CSPs).
Traditional RAN networks currently use area wide Self-Organizing Network (SON) models for exercising Radio Resource Management (RRM) and configuration management optimization decisions at a per-cell level. They rely on single control loop, leverage key performance indicators (KPIs) and analytics for such control decisions at non-real time (Non-RT) granularities.
Mavenir’s O-RIC surpasses the capabilities of SON with two control loops:
- Non-RT O-RIC — Typically deployed in a centralized cloud, it builds advanced Machine Learning (ML) algorithms using long-term RAN data to define dynamic and adaptive policies to control and optimize network performance and configuration management decisions. Non-RT RIC can also be used in existing legacy networks, adding another performance layer through ML for policy control.
- Near-real time (Near-RT) O-RIC — Deployed at or towards the edge, it uses a low latency control loop that optimizes RAN activity at both the cell and individual user equipment (UE) level by hosting trained Artificial Intelligence (AI) and ML applications to infer and control Open RAN elements in near-RT. The near-RT O-RIC intelligently optimizes UE-level control-plane call processing and user-plane data transfer decisions. This level of granularity is not available in SON.
Mavenir’s O-RIC is a business results tool, that enables intent-based decisions by setting granular performance targets—at the cell or even individual UE level—to generate business outcomes, such as the generation of additional revenue (enabling an SLA that generates a premium service), the reduction in network cost through the optimization of resources (energy savings, spectral efficiency, etc.), or the improvement of the end user experience (by improving throughput, reducing latency and connection drops, and expanding coverage). The NIaaS signature framework of Mavenir’s RIC accomplishes this goal by offering fine-grained predictive intelligence and advanced analytics about the RAN to third party applications (rApps and xApps), integrated with Mavenir’s O-RIC, towards optimizing the network performance.
Mavenir’s O-RIC shifts control from the vendor ecosystem to the operator by delivering an Open API framework that allows the implementation of standards-based rApps and xApps for different business outcomes, such as energy savings, traffic steering, massive MIMO optimization, spectral efficiency improvements, and RAN slice assurance. Proprietary radio access solutions limit the choice to what their vendor has to offer and open up the network to fine-grained per user data-driven optimization. With Mavenir’s RIC, applications can be developed by an in-house team or purchased in an "app store" from any Open RAN compliant third party.
"Creating real business value for next-generation Open RAN networks requires deep telco domain expertise and a disruptive approach to network intelligence," said Brandon Larson, SVP & GM of the Multimedia Business Unit at Mavenir. "As a pioneer in cloud-native solutions at a massive scale, Mavenir is leading the way with award-winning Open vRAN solutions, layered with O-RIC AI and ML algorithms and applications, which create operator customizable business outcomes based on target objectives to solve unique business problems and give control of the network back to the CSP."
Mavenir's O-RIC offers unparalleled benefits in terms of (i) Network performance, (ii) User Experience, (iii) Reduced TCO, (iv) Simplified cloud-native deployments, (v) new revenue sources, etc.
For more information visit the Mavenir Open RAN Intelligent Controller page.
Mavenir is exhibiting at Mobile World Congress 2023 in Barcelona, Spain at the Fira Gran Via in Hall 2, stand 2H60. Click here to find out more.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230210005022/en/
Contact information
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 15:30:00 EEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 15:00:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. RLS-1496 is a first-in-class disease-modifying selective glutathione peroxidase 4 (GPX4) modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process. The study is expected to begin in Q4 2025. The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin); study results are expected in Q4 2025. Actinic keratosis is a rough, scaly patch caused by sun exposure that appears on sun-exposed areas of the skin, such as
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 15:00:00 EEST | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers to higher-acuity care units, achieved through earlier detection and intervention to prevent patient deterioration.2-5 Now, in this new retrospective analysis – involving 3-1/2 years of data and almost
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom